• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Clinical Trials in Russia: SynRG Orange Paper Q1

Clinical Trials in Russia: SynRG Orange Paper Q1

June 9, 2009
CenterWatch Staff

On June 1, 2009, Synergy Research Group (SynRG), a Russia-based CRO, presented the English version of SynRG Orange Paper Q1 2009, a regular analytical report on the clinical trial market in Russia. The report contains hundreds of figures as well as dozens of tables covering various aspects of the Russian clinical trial market.

The Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (RosZdravNadzor, RZN) approved 113 new clinical trials during Q1 2009, a 13% decrease over the corresponding period of last year.

Clinical trials in Russia in Q1 2009 were sponsored by companies from 28 countries. Russian sponsors initiated the most new clinical trials (31), followed by American sponsors with 20, German sponsors with 12, and eight each by Swiss and Japanese sponsors and seven by UK sponsors.

Four new phase I studies were launched in the first quarter of 2009, three trials fewer than in the corresponding quarter of last year. The number of phase II trials notably decreased from 41 trials in the first quarter of 2008 to 26 in the first quarter of 2009. Despite the overall trend, the number of phase III trials demonstrated a slight increase over last year's number, up from 54 to 59 studies. The number of phase IV trials slightly decreased from 12 in Q1 2008 to nine new studies in Q1 2009.

The number of patients to be enrolled in phase II-IV trials launched in the first quarter of 2009 stood at 9,784 patients, nearly the same as last year's number.

Seventy percent of the new clinical in Q1 2009 were conducted in six therapeutic areas: 17 were initiated in cardiovascular diseases; 16 in neurology and oncology; 14 in infectious diseases; 12 in respiratory diseases; and 11 in endocrinology.

Synergy Research Group (SynRG) is a Russia-based full-service contract research organization established in 2002. Synergy Research Group is represented in Saint-Petersburg, Novosibirsk, Yekaterinburg, Perm and Almaty (Kazakhstan), with company headquarters in Moscow.

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing